Retinoid/NN
X/NN
receptor/NN
(/(
RXR/NN
)/)
agonist-induced/JJ
activation/NN
of/IN
dominant-negative/JJ
RXR-retinoic/JJ
acid/NN
receptor/NN
alpha403/NN
heterodimers/NNS
is/VBZ
developmentally/RB
regulated/VBN
during/IN
myeloid/JJ
differentiation/NN
./.

The/DT
multiple/JJ
biologic/JJ
activities/NNS
of/IN
retinoic/JJ
acid/NN
(/(
RA/NN
)/)
are/VBP
mediated/VBN
through/IN
RAR/NN
and/CC
retinoid/NN
X/NN
receptor/NN
(/(
RXR/NN
)/)
nuclear/JJ
receptors/NNS
that/WDT
interact/VBP
with/IN
specific/JJ
DNA/NN
target/NN
sequences/VBZ
as/IN
heterodimers/NNS
(/(
RXR-RAR/NN
)/)
or/CC
homodimers/NNS
(/(
RXR-RXR/NN
)/)
./.
=====
RA/NN
receptor/NN
activation/NN
appears/VBZ
critical/JJ
to/TO
regulating/VBG
important/JJ
aspects/NNS
of/IN
hematopoiesis/NN
,/,
since/IN
transducing/VBG
a/DT
COOH-terminally/RB
truncated/VBN
RARalpha/NN
exhibiting/VBG
dominant-negative/JJ
activity/NN
(/(
RARalpha403/NN
)/)
into/IN
normal/JJ
mouse/NN
bone/NN
marrow/NN
generates/VBZ
hematopoietic/JJ
growth/NN
factor-dependent/JJ
cell/NN
lines/NNS
frozen/VBN
at/IN
the/DT
multipotent/JJ
progenitor/NN
(/(
EML/NN
)/)
or/CC
committed/VBN
promyelocyte/JJ
(/(
MPRO/NN
)/)
stages/NNS
./.
=====
Nevertheless/RB
,/,
relatively/RB
high/JJ
,/,
pharmacological/JJ
concentrations/NNS
of/IN
RA/NN
(/(
1/CD
to/TO
10/CD
&/CC
mgr/NN
;/:
M/NN
)/)
overcome/VBP
these/DT
differentiation/NN
blocks/NNS
and/CC
induce/VBP
terminal/JJ
granulocytic/JJ
differentiation/NN
of/IN
the/DT
MPRO/NN
promyelocytes/NNS
while/IN
potentiating/VBG
interleukin-3/NN
(/(
IL-3/NN
)/)
-induced/JJ
commitment/NN
of/IN
EML/NN
cells/NNS
to/TO
the/DT
granulocyte/monocyte/NN
lineage/NN
./.
=====
In/IN
the/DT
present/JJ
study/NN
,/,
we/PRP
utilized/VBD
RXR-/NN
and/CC
RAR-specific/JJ
agonists/NNS
and/CC
antagonists/NNS
to/TO
determine/VB
how/WRB
RA/NN
overcomes/VBZ
the/DT
dominant-negative/JJ
activity/NN
of/IN
the/DT
truncated/VBN
RARalpha/NN
in/IN
these/DT
different/JJ
myeloid/JJ
developmental/JJ
stages/NNS
./.
=====
Unexpectedly/RB
,/,
we/PRP
observed/VBD
that/IN
an/DT
RXR-specific/JJ
,/,
rather/RB
than/IN
an/DT
RAR-specific/JJ
,/,
agonist/NN
induces/VBZ
terminal/JJ
granulocytic/JJ
differentiation/NN
of/IN
MPRO/NN
promyelocytes/NNS
,/,
and/CC
this/DT
differentiation/NN
is/VBZ
associated/VBN
with/IN
activation/NN
of/IN
DNA/NN
response/NN
elements/NNS
corresponding/VBG
to/TO
RAR-RXR/NN
heterodimers/NNS
rather/RB
than/IN
RXR-RXR/NN
homodimers/NNS
./.
=====
This/DT
RXR/NN
agonist/NN
activity/NN
is/VBZ
blocked/VBN
by/IN
RAR-specific/JJ
antagonists/NNS
,/,
suggesting/VBG
extensive/JJ
cross-talk/NN
between/IN
the/DT
partners/NNS
of/IN
the/DT
RXR-RARalpha403/NN
heterodimer/NN
./.
=====
In/IN
contrast/NN
,/,
in/IN
the/DT
more/RBR
immature/JJ
,/,
multipotent/JJ
EML/NN
cells/NNS
we/PRP
observed/VBD
that/IN
this/DT
RXR-specific/JJ
agonist/NN
is/VBZ
inactive/JJ
either/CC
in/IN
potentiating/VBG
IL-3-mediated/JJ
commitment/NN
of/IN
EML/NN
cells/NNS
to/TO
the/DT
granulocyte/NN
lineage/NN
or/CC
in/IN
transactivating/VBG
RAR-RXR/NN
response/NN
elements/NNS
./.
=====
RA-triggered/JJ
GALdbd-RARalpha/NN
hybrid/NN
activity/NN
in/IN
these/DT
cells/NNS
indicates/VBZ
that/IN
the/DT
multipotent/JJ
EML/NN
cells/NNS
harbor/VBP
substantial/JJ
nuclear/JJ
hormone/NN
receptor/NN
coactivator/NN
activity/NN
./.
=====
However/RB
,/,
the/DT
histone/NN
deacetylase/NN
(/(
HDAC/NN
)/)
inhibitor/NN
trichostatin/NN
A/NN
readily/RB
activates/VBZ
an/DT
RXR-RAR/NN
reporter/NN
construct/NN
in/IN
the/DT
multipotent/JJ
EML/NN
cells/NNS
but/CC
not/RB
in/IN
the/DT
committed/VBN
MPRO/NN
promyelocytes/NNS
,/,
indicating/VBG
that/IN
differences/NNS
in/IN
HDAC-containing/JJ
repressor/NN
complexes/NNS
in/IN
these/DT
two/CD
closely/RB
related/JJ
but/CC
distinct/JJ
hematopoietic/JJ
lineages/NNS
might/MD
account/VB
for/IN
the/DT
differential/JJ
activation/NN
of/IN
the/DT
RXR-RARalpha403/NN
heterodimers/NNS
that/WDT
we/PRP
observed/VBD
at/IN
these/DT
different/JJ
stages/NNS
of/IN
myeloid/JJ
development/NN
./.